Patent assignee · FR · COMPANY

Eligo Bioscience

🏢 View company profile →
36Patents
36Active
36Granted
66Portfolio score

Filing activity: Feb 2, 2018 → Jul 24, 2024

Most-cited patents

PatentTitleAreaCited byStatus
US11224621B2 Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders Chemistry; Metallurgy 4 Active
US10808254B2 Optimized vector for delivery in microbial populations Emerging Cross-Sectional Technologies 3 Active
US11236133B2 Chimeric receptor binding proteins for use in bacterial delivery vehicles Chemistry; Metallurgy 3 Active
US11357831B2 Sequence-specific antimicrobials by blocking DNA repair Emerging Cross-Sectional Technologies 2 Active
US11208437B2 Branched receptor binding multi-subunit protein complexes for use in bacterial delivery vehicles Chemistry; Metallurgy 2 Active
US11690880B2 Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders Chemistry; Metallurgy 2 Active
US11541106B2 Method for killing bacteria with an engineered postbiotic Emerging Cross-Sectional Technologies 2 Active
US11078490B2 Optimized vector for delivery in microbial populations Emerging Cross-Sectional Technologies 2 Active
US11746352B2 Microbiome modulation of a host by delivery of DNA payloads with minimized spread Chemistry; Metallurgy 2 Active
US11534467B2 Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders Chemistry; Metallurgy 1 Active
US11124776B2 Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof Emerging Cross-Sectional Technologies 1 Active
US11376286B2 Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders Chemistry; Metallurgy 1 Active
US11739304B2 Production of lytic phages Chemistry; Metallurgy 1 Active
US11584918B2 Transcriptional control in prokaryotic cells using DNA-binding repressors Chemistry; Metallurgy 1 Active
US11697802B2 Production bacterial cells and use thereof in production methods Chemistry; Metallurgy 0 Active
US11633348B2 Cosmetic use of engineered postbiotics comprising bacteriocins and/or endolysins Human Necessities 0 Active
US11840695B2 Recombinant C. acnes phages comprising transgenes Chemistry; Metallurgy 0 Active
US12214070B2 Cosmetic use of engineered postbiotics comprising bacteriocins and/or endolysins Human Necessities 0 Active
US11473093B2 Cutibacterium acnes recombinant phages, method of production and uses thereof Chemistry; Metallurgy 0 Active
US11939598B2 Production bacterial cells and use thereof in production methods Chemistry; Metallurgy 0 Active
US11970716B2 Transcriptional control in prokaryotic cells using DNA-binding repressors Chemistry; Metallurgy 0 Active
US11820989B2 Phage-derived particles for in situ delivery of DNA payload into C. acnes population Chemistry; Metallurgy 0 Active
US11839645B2 Therapeutic use of engineered postbiotics comprising bacteriocins and/or endolysins Emerging Cross-Sectional Technologies 0 Active
US12414962B2 Method for treating C. acnes bacteria-associated diseases Chemistry; Metallurgy 0 Active
US11952595B2 Production of lytic phages Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.